A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 511 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Unravelling the mystery of Barrett’s oesophagus October 25, 2021 FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection... April 25, 2023 6 Habits That Can Help You Feel More in Control of... November 30, 2022 A urine test for bladder cancer: What’s the latest? April 16, 2022 Load more HOT NEWS A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in... Cancer Research UK thanks Tania Bryer for a decade of fundraising... Nurse Who Battled Cancer While In School Surprises Her Dad With... pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue...
